GEFTIB 250MG TAB is a prescription medication used to treat certain types of non-small cell lung cancer (NSCLC) that has spread to other parts of the body.
Composition:
Each tablet of GEFTIB 250MG TAB contains 250mg of gefitinib.
Mechanism of Action:
Gefitinib works by:
- Inhibiting the action of epidermal growth factor receptor (EGFR), a protein that helps cancer cells grow and multiply
- Blocking the signaling pathways that allow cancer cells to grow and divide
- Causing cancer cells to die or stop growing
Uses:
GEFTIB 250MG TAB is used to treat NSCLC that has:
- EGFR mutations in the tumor cells
- Spread to other parts of the body
- Not responded to other treatments
Dosage:
The recommended dosage of GEFTIB 250MG TAB is:
- 250mg taken orally once daily, with or without food
Side Effects:
Common side effects of GEFTIB 250MG TAB include:
- Diarrhea
- Fatigue
- Skin rash
- Nausea and vomiting
- Hair loss
- Abnormal liver function tests
- Increased risk of respiratory infections
Recommendation:
GEFTIB 250MG TAB is recommended for patients who have not responded to other treatments for their NSCLC. Patients should also be advised to monitor their blood counts and liver function regularly during treatment.
Important Note:
Patients should not take GEFTIB 250MG TAB if they have a history of severe allergic reactions, kidney problems, or liver problems. Patients should also inform their healthcare provider if they have any underlying medical conditions, such as heart problems or lung problems, before taking GEFTIB 250MG TAB.
Some common brands of gefitinib include:
- Iressa (AstraZeneca)
- Zeptol (AstraZeneca)
Please note that GEFTIB 250MG TAB is not available in all markets and may be approved for different indications and dosages in different regions.
It’s worth noting that GEFTIB 250MG TAB is a targeted therapy, meaning it is designed to specifically target the EGFR protein in cancer cells, which can lead to more effective treatment with fewer side effects.
Reviews
There are no reviews yet.